Scilex Holding Company (SCLX) - Total Liabilities
Based on the latest financial reports, Scilex Holding Company (SCLX) has total liabilities worth $564.05 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SCLX long-term investment intensity to see how much of total assets are deployed in long-term investments.
Scilex Holding Company - Total Liabilities Trend (2020–2025)
This chart illustrates how Scilex Holding Company's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Scilex Holding Company asset portfolio.
Scilex Holding Company Competitors by Total Liabilities
The table below lists competitors of Scilex Holding Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WIZIT Co. Ltd
KQ:036090
|
Korea | ₩273.85 Billion |
|
GigCapital7 Corp. Class A Ordinary Share
NASDAQ:GIG
|
USA | $70.99 Million |
|
TGI Infrastructures Ltd
TA:TGI
|
Israel | ILA93.89 Million |
|
Jaba I Inversiones Inmobiliarias Socimi SA
MC:YABA
|
Spain | €11.98 Million |
|
Reino Capital SA
WAR:RNC
|
Poland | zł36.69 Million |
|
MNC Vision Networks PT
JK:IPTV
|
Indonesia | Rp1.02 Trillion |
|
Hankuk Steel Wire Co. Ltd
KQ:025550
|
Korea | ₩160.29 Billion |
|
Comunication Weaver Co.Ltd
KQ:056360
|
Korea | ₩27.91 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Scilex Holding Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Scilex Holding Company (SCLX) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scilex Holding Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scilex Holding Company (2020–2025)
The table below shows the annual total liabilities of Scilex Holding Company from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $576.73 Million | +101.94% |
| 2024-12-31 | $285.59 Million | +4.14% |
| 2023-12-31 | $274.25 Million | +445.35% |
| 2022-12-31 | $50.29 Million | -83.34% |
| 2021-12-31 | $301.81 Million | +35.23% |
| 2020-12-31 | $223.19 Million | -- |
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more